William Charles Kovacs net worth and biography

William Kovacs Biography and Net Worth

Insider of Olema Pharmaceuticals

Mr. Kovacs joined Olema in June 2020 as Chief Operating and Financial Officer bringing strong biotech leadership experience combined with strategic advisory and capital markets expertise. His demonstrated track record of leading the build-out and growth of emerging biopharma companies is highlighted by a strong strategic and business acumen with a focus on execution. Before Olema, Shane was Chief Business and Financial Officer at BlueRock Therapeutics LP, an engineered cell therapy company focused on neurology, immunology and cardiology, which was acquired by Bayer AG in September 2019. As the Chief Financial Officer of PTC Therapeutics Inc., Shane led the company through its 2013 IPO, a series of financings, partnerships and acquisitions and played a key role in the global commercialization of Translarna^TM. Earlier in his career, Shane held senior investment banking roles including Managing Director, Healthcare Investment Banking, at Credit Suisse, and Managing Director, Head of Biotechnology Investment Banking at RBC Capital Markets where he was involved in the successful execution of over $40 billion in financings and mergers & acquisitions. He received degrees in chemical engineering, medical sciences and economics from Queen’s University, Canada and an M.B.A. from the University of Western Ontario. He is also a CFA charterholder.

What is William Charles Kovacs' net worth?: The estimated net worth of William Charles Kovacs is at least $3.61 million as of January 15th, 2026. Kovacs owns 139,727 shares of Olema Pharmaceuticals stock worth more than $3,608,590 as of February 6th. This net worth approximation does not reflect any other investments that Kovacs may own. Additionally, Kovacs receives an annual salary of $820,370.00 as Insider at Olema Pharmaceuticals. Learn More about William Charles Kovacs' net worth.
How old is William Charles Kovacs?: Kovacs is currently 50 years old. There are 4 older executives and no younger executives at Olema Pharmaceuticals. The oldest executive at Olema Pharmaceuticals is Dr. David C. Myles Ph.D., Chief Discovery & Non-Clinical Development Officer, who is 61 years old. Learn More on William Charles Kovacs' age.
What is William Charles Kovacs' salary?: As the Insider of Olema Pharmaceuticals, Inc., Kovacs earns $820,370.00 per year. The highest earning executive at Olema Pharmaceuticals is Dr. Sean P. Bohen M.D., Ph.D., President, CEO & Director, who commands a salary of $1,150,000.00 per year. Learn More on William Charles Kovacs' salary.
How do I contact William Charles Kovacs?: The corporate mailing address for Kovacs and other Olema Pharmaceuticals executives is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. Olema Pharmaceuticals can also be reached via phone at 650-243-5555 and via email at [email protected]. Learn More on William Charles Kovacs' contact information.
Has William Charles Kovacs been buying or selling shares of Olema Pharmaceuticals?: Over the course of the past ninety days, William Charles Kovacs has sold $2,980,054.22 in Olema Pharmaceuticals stock. Most recently, Shane William Charles Kovacs sold 100,000 shares of the business's stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $28.73, for a transaction totalling $2,873,000.00. Following the completion of the sale, the insider now directly owns 139,727 shares of the company's stock, valued at $4,014,356.71. Learn More on William Charles Kovacs' trading history.
Who are Olema Pharmaceuticals' active insiders?: Olema Pharmaceuticals' insider roster includes Sean Bohen (CEO), Ian Clark (Director), Cyrus Harmon (CTO), Kinney Horn (Insider), William Kovacs (Insider), David Myles (Chief Discovery and Non-Clinical Development Officer), and Naseem Zojwalla (Chief Medical Officer). Learn More on Olema Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Olema Pharmaceuticals?: During the last twelve months, insiders at the sold shares 16 times. They sold a total of 790,501 shares worth more than $22,257,272.41. The most recent insider tranaction occured on January, 20th when Director Cyrus Harmon sold 10,000 shares worth more than $268,800.00. Insiders at Olema Pharmaceuticals own 16.4% of the company. Learn More about insider trades at Olema Pharmaceuticals.
Information on this page was last updated on 1/20/2026.

William Charles Kovacs Insider Trading History at Olema Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/15/2026	Sell	100,000	$28.73	$2,873,000.00	139,727
1/13/2026	Sell	3,822	$28.01	$107,054.22	239,727

William Charles Kovacs Buying and Selling Activity at Olema Pharmaceuticals

Olema Pharmaceuticals Company Overview

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $25.83

$25.46

$26.48

50 Day Range

MA: $27.49

$24.57

$35.83

2 Week Range

Now: $25.83

$2.86

$36.26

Volume

359,777 shs

Average Volume

1,297,326 shs

Market Capitalization

$1.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

William Kovacs Biography and Net Worth

What is William Charles Kovacs' net worth?

How old is William Charles Kovacs?

What is William Charles Kovacs' salary?

How do I contact William Charles Kovacs?

Has William Charles Kovacs been buying or selling shares of Olema Pharmaceuticals?

Who are Olema Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Olema Pharmaceuticals?